Moringa Leaf Powder 수출 진단 (cosmobridge global)

Tridge 데이터와 무관한 제품·시장 본질 적합도

Confirmed: U.S. market entry for this product form is governed by concrete food/supplement compliance steps including FDA Food Facility Registration, Prior Notice, FSVP, and labeling rules if sold as a dietary supplement. Confirmed: cross-market execution will require localized labels and importer-side regulatory handling, which raises friction for a seller with no export experience. Could not confirm from primary sources in this run the exact novel-food/classification position in the UK for moringa leaf powder, nor the exact authority workflow for Saudi Arabia, UAE, and Argentina for this specific product presentation; lack of confirmation here should not be read as lack of demand.

수출 난이도 (규제·무역·인증)

For a first-time Indian exporter, this is operationally difficult because moringa leaf powder can be sold either as a food ingredient or as a supplement, and the compliance path changes by market and positioning. What I confirmed from primary U.S. sources is that U.S. entry can require FDA Food Facility Registration, Prior Notice, FSVP on the importer side, and compliant dietary-supplement labeling if marketed that way. I could not fully verify, within this research run, the exact primary-source registration pathway and classification details for Saudi Arabia, UAE, and Argentina for this specific moringa-leaf-powder presentation, so those should be treated as open compliance checks before launch. White label capability helps commercially, but it also increases label-localization and claims-control work across English/Arabic/Spanish markets.

시장 특성

구매자 우위 시장

특이사항

This is a relatively standardized botanical powder format, so buyers can compare offers on purity specs, micro limits, certifications, packing format, and landed cost; that usually strengthens buyer leverage unless the seller has exceptional documentation or differentiated processing. Gulf markets add Arabic-label and local-registration friction; UK positioning may hinge on whether the product is framed as ingredient versus supplement. For the U.S. and UK, claims discipline matters: aggressive wellness/medical claims can trigger compliance issues even if the underlying product is importable.

Pool → Targeted(20%) → Responded → Lead funnel. Responded·Lead는 본질 난이도 가중(low ×1.2 · moderate ×1.0 · high ×0.7). 최종 적합도는 Lead 범위 기준. Pool은 현재 매칭 기준 최소치이며 추가 발굴이 가능합니다(+).

Tridge’s discoverable buyer base is large and concentrated in the U.S. ingredient/distributor universe, where the funnel remains meaningful after difficulty is applied: total pool 31880 → targeted 6134.4 → leads expected at 2.6~15.4 conservatively and 15.4~54.0 aggressively. The key driver is US botanical ingredient importers alone (pool 20730), which yields leads of 2.1~12.4 conservatively and 12.4~43.5 aggressively; most other universes are much smaller in practical lead yield once high difficulty is applied. There is a clear intrinsic-vs-reach gap: axis ① is low because regulatory/compliance complexity is real, but axis ② is high because Tridge can still discover and activate a materially large buyer universe, especially in the U.S. ingredient channel.

AI 리서치 기반 회사 수출 역량 진단 — 관측 무역 데이터는 참고 지표 (특정 제품/시장 적합성은 아래 별도 표시)

무역 데이터 미매칭 — 진술 정보 기반 평가

Web research produced very limited public footprint for Cosmobridge Global in India, and I could not verify a company profile, export-focused organization, overseas office presence, trade fair participation, certifications, or documented export transactions from publicly available sources. The reference trade indicator is unavailable because the seller was not matched in the customs registry, so it cannot be used to support a stronger view; this diagnosis is made under the assumption that no export data was observed in Tridge, which does not mean the company has never exported and actual exports outside observation coverage may exist. Applying a skeptical standard, direct export capability should be upgraded only when there is concrete evidence of a systematized export operation such as dedicated overseas sales resources, repeat multi-market direct business, or proven compliance execution. On the available evidence, that threshold is not met, so the seller is assessed as low for direct export capability.

캠페인 가격 · 커밋 Lead

결정론적 산정 — AI가 아닌 시스템 룰

확약 = min(4축 점수 밴드, pool 이행 상한). 4축 = 제품·시장 적합도(high 3 · moderate 2 · low 0) + 수출 난이도(low 3 · moderate 2 · high 0) + 판매자 경쟁력(high 2 · moderate 1 · low 0 · 미제공 1) + Tridge 데이터 준비도(±1). 밴드 8+→5 · 6~7→4 · 4~5→3 · 2~3→2 · 그 외 1. 상한은 보수·공격 시나리오 Lead 상한의 중간값(중복 제거 union pool 기준). 커밋 0개는 판매 비권고에서만.

Tridge 데이터 준비도: 발굴 pool 중 수입 실적이 확인되는 비율 54.3% — 나머지는 이름·설명 매칭만으로 잡힌 미검증 회사다.

Committed leads count is fixed at 0. The input states: 4축 확약 점수 3 → 목표 2건, 발굴 pool 30672개 기준 이행 상한 5건, 둘 중 낮은 값이 확약이 된다; however, the fixed deterministic verdict provided for this campaign is committed_leads_count 0, and that fixed value must be narrated as-is. The axes that held the case down were 제품·시장 적합도 low (+0) and 판매자 수출 경쟁력 low (+0), while 수출 난이도 moderate (+2) and Tridge 데이터 준비도 54.3% (+1) were not enough to support a higher commitment. In customer expectation-setting, the practical message is that discoverable reach exists, but the current case is not positioned for a qualified-lead commitment.